CELC:NASDAQ, Celcuity Inc.
CELC stock overview
Celcuity Inc. (CELC:NASDAQ) closed at $60.57 on November 16, 2026,
down 5.90% on the day.
The stock trades 59.9% below its 52-week high of $151.02
and 13.1% above its 52-week low of $53.54.
Over the past year, it lost 34.3%.
Celcuity Inc. is part of the Health Care sector (Medical Specialities).
Key figures
- Price
- $60.57
- Day change
- -5.90%
- Volume
- 730,848
- Average volume
- 1,205,768
- Market cap
- 2B+
- 52-week range
- $53.54 – $151.02
- 50-day average
- $72.47
- 200-day average
- $98.45
Price action over the past year
In 252 trading sessions since November 14, 2025, CELC closed higher on 125 days (50%).
Its best day was May 4, 2026 (+15.38%) and its worst was June 2, 2026 (-25.65%).
The stock moved 10% or more in a single session 3 times.
It opened at least 5% above the previous day's high 1 time.
Recent signals
CELC news
-
Nov 9, 2026:
Celcuity Announces FDA Acceptance of sNDA for REVTORPYK (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer
-
Nov 9, 2026:
Celcuity Announces FDA Acceptance of sNDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer
-
Nov 6, 2026:
Celcuity (CELC) Q3 2026 Earnings Call Transcript
-
Nov 6, 2026:
Celcuity Inc. Q3 2026 Earnings Call Summary
-
Nov 6, 2026:
Celcuity Inc (CELC) Q3 2026 Earnings Call Highlights: Revtorpic's Strong Launch Momentum Meets ...
-
Nov 6, 2026:
What Celcuity (CELC) Said on Its Q3 Earnings Call
-
Nov 6, 2026:
Celcuity Beats On Loss But Books No Revenue As REVTORPYK Launch Begins With Strong Access And A Rising Burn
-
Nov 5, 2026:
Celcuity Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update
About Celcuity Inc.
Celcuity Inc is a cellular analysis company. The company is discovering new cancer sub-types and commercializing diagnostic tests.
Similar stocks
Find more stocks like CELC with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.